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Abstract
Preventive vaccination is a highly promising strategy for interrupting leishmaniasis trans-
mission that can, additionally, contribute to elimination. A vaccine formulation based on nat-
urally excreted secreted (ES) antigens was prepared from L. infantum promastigote culture
supernatant. This vaccine achieved successful results in Phase III trials and was licensed
and marketed as CaniLeish. We recently showed that newly identified ES promastigote sur-
face antigen (PSA), from both viable promastigotes and axenically-grown amastigotes, rep-
resented the major constituent and the highly immunogenic antigen of L. infantum and L.
amazonensis ES products. We report here that three immunizations with either the recombi-
nant ES LaPSA-38S (rPSA) or its carboxy terminal part LaPSA-12S (Cter-rPSA), combined
with QA-21 as adjuvant, confer high levels of protection in naive L. infantum-infected Beagle
dogs, as checked by bone marrow parasite absence in respectively 78.8% and 80% of vac-
cinated dogs at 6 months post-challenge. The parasite burden in infected vaccinated dogs
was significantly reduced compared to placebo group, as measured by q-PCR. Moreover,
our results reveal humoral and cellular immune response clear-cut differences between
vaccinated and control dogs. An early increase in specific IgG2 antibodies was observed in
rPSA/QA-21- and Cter-rPSA/QA-21-immunized dogs only. They were found functionally
active in vitro and were highly correlated with vaccine protection. In vaccinated protected
dogs, IFN-γ and NO productions, as well as anti-leishmanial macrophage activity, were
increased. These data strongly suggest that ES PSA or its carboxy-terminal part, in recom-
binant forms, induce protection in a canine model of zoonotic visceral leishmaniasis by
inducing a Th1-dominant immune response and an appropriate specific antibody response.
These data suggest that they could be considered as important active components in vac-
cine candidates.
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Author Summary
Visceral leishmaniasis (VL), a potentially fatal disease caused by L. infantum, represents
perfectly the need for a “One Health” approach for disease control, since it affects both
humans and dogs, with similar clinical outcome and T-cell mediated immunity commit-
ment. The dog vaccine development is highly required as our present resources for VL
treatment and control have a limited effectiveness. It would represent the most convenient
and efficient control way to decrease the dog-sandfly-dog transmission cycle, essential for
human incidence reduction. The results indicate that recombinant forms of soluble pro-
mastigote surface antigen (PSA) are very promising effective vaccine candidates against
canine VL. The elicited immune responses effectively reduced parasite load in in vitro pre-
infected macrophages and in experimentally infected dogs. Through this approach, we
aim to reduce the number of infected animals developing progressive infections thereby
positively influencing human public health.
Introduction
Leishmaniasis is among the most severe parasitic infections affecting humans and dogs in the
world. It is the second-highest number of deaths caused by parasites worldwide. Leishmaniasis
is remarkably associated with poverty and is an important part of neglected and uncontrolled
tropical diseases [1]. Infection is provoked by protozoans of the genus Leishmania, transmitted
by the bite of different species of phlebotomine sandflies. They replicate within host mononu-
clear phagocytes [2–4]. In humans, Leishmania parasites cause a wide spectrum of human dis-
eases ranging from asymptomatic disease, self-healing cutaneous (CL), to disfiguring diffuse
cutaneous leishmaniasis (DCL) or mutilating mucosal infections (MCL), and from subclinical
to acute visceral disease (VL) that results in death in susceptible people, causing more than
59,000 deaths annually [1,5].
Anthroponotic visceral leishmaniasis in India and in Central Africa is caused by L. dono-
vani and is characterized by the absence of animal reservoirs, making man the disease reser-
voir. Canids (wild and domestic) are unequivocally recognized as the main reservoir,
continuously supplying the transmission cycle of Leishmania infantum in Old World and L.
chagasi (its synonym in the NewWorld). Zoonotic VL is found in the Mediterranean region,
several Middle East, African and Asian countries, in South and Central America and probably
in southern US [6–8]. VL increased incidence and severity are linked to parasite reservoir
migrations, new insect vector localization due to environmental changes, co-infection with
immunosuppressive diseases, disease urbanization, deforestation, and poverty [9–13]. In
southwestern Europe, at least 2.5 million dogs are probably infected [14] and involved in the
transmission cycle of L. infantum in humans. In the absence of effective and low-cost drugs
for mass administration, priority control measures for elimination aim at reducing the trans-
mission of VL. They include clinical, serological and parasitological diagnosis, treatment by
chemotherapy, reduction of the vector population and preventive infectious sandfly bites by
using several topical insecticides [15]. These actions are difficult to improve, expensive and
weakly effective. Therefore, preventive canine vaccination is a highly promising strategy for
interrupting VL transmission and could contribute to elimination [11,16]. Furthermore, vac-
cine development is a promising perspective for human leishmaniasis, as a successful chemo-
therapy restores impaired cellular immune responses [17] and individuals recovering from
leishmaniasis are usually protected against a further infection [18–21]. The elaboration of a
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safe, efficient and inexpensive anti-leishmanial vaccine provides a substantial goal for global
public health for animals and humans.
Our interest in Leishmania ES molecules was supported by previous studies showing their
immunological properties on macrophage functions and in protection against challenge [22–
29]. In recent years, a vaccine based on L. infantum promastigote ES (LiESAp) achieved suc-
cessful results in Phase III trials [23,28]. This vaccine was commercialized in Europe as CaniLe-
ish since 2011 [23,28,30]. A prototype of this vaccine (LiESAp/MDP) conferred 93%
protection under field condition in France [28]. CaniLeish (LiESAp/QA-21) vaccine provided
a significant reduction in the risk of progressing to active infection or overt disease with a clini-
cal efficacy of 68% [30] in a context of a cumulative incidence of 80% of Leishmania infection
[31]. More recently, we identified and characterized LaPSA-38S and LiPSA-50S as major
immunodominant ES components of L. amazonensis and L. infantum promastigotes, respec-
tively [32]. These proteins were selectively recognized by vaccinated and protected dogs and
human cells from immune individuals [24,32]. Members of this multi-gene family and the exis-
tence of membrane-bound members of the PSA family, such as the PSA-2 gene, have been well
documented [33–37]. Leishmania PSA proteins are involved in resistance to complement lysis
and in macrophage adhesion/invasion via the complement receptor 3 (CR3) [38,39]. PSA-2
complex proteins induce a potent Th1 response in humans [40], and confer protection against
a virulent challenge in mice [41]. In L. infantum and L.major-protected humans, we also
clearly demonstrated that the native ES LaPSA-38S protein in recombinant form (rPSA) evi-
denced a Th1-dominant response within an overall mixed Th1/Th2 profile and a cytotoxic
response [24]. We hypothesize that this molecule might represent a potential candidate for a
next second generation vaccine design.
Current recombinant technology leading to a highly purified/defined vaccine formulation
increased vaccine safety, stability and reproducibility by decreasing batch to batch variation,
compared to the already licensed first generation vaccines. This strategy should decrease the
risk of adverse reactions associated with complex vaccine. Moreover, administering just the
most immunogenic protein produces a more targeted immune response focused on identified
protective antigens. We report here a vaccination trial on naive dogs using the recombinant ES
LaPSA-38S antigen (rPSA) expressed in L. tarentolae cultured in defined serum-free medium
or its carboxy terminal part (Cter-rPSA) expressed in E. coli. Recombinant LaPSA-12S antigen
(Cter-rPSA) is a truncated polypeptide corresponding to the protease-resistant immunodomi-
nant carboxyl-terminal domain of the protein [42]. In this first investigation using these
recombinant proteins and including a limited number of animals in a short term survey, dogs
were randomly included into three experimental groups that received three subcutaneous
injections at 4-week interval of either buffer saline or adjuvanted rPSA or adjuvanted Cter-
rPSA. Vaccinated dogs had significantly higher levels of specific and efficient IgG2 antibodies
and developed an early and specific Th1-dominant cellular immune response (increased NO-
mediated anti-leishmanial macrophage activity in response to higher levels of IFN-γ). This
dominant Th1 immune profile was found to be correlated with a good protection against an
intravenous L. infantum promastigote challenge.
Results
Clinical evolution of dogs
No local and/or general adverse reactions, no hyperthermia, no body weight loss were seen in
all immunized dogs upon vaccination. The candidate vaccine tolerance was satisfactory.
Immunized dogs were checked monthly for the appearance of external clinical manifesta-
tions until 6 months after administration of the parasites. No obvious clinical signs of
Excreted/Secreted PSA Protection in Dogs
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004614 May 25, 2016 3 / 18
leishmaniasis were noted in any of the dogs from the vaccinated and placebo groups until 6
months after challenge.
Parasitological evolution of dogs
The occurrence of parasites in sub-cultures (Fig 1A), the presence of parasite DNA (Fig 1B)
and the parasite loads using q-PCR (Fig 1C) were determined in bone marrow aspirates for the
three groups of dogs at 2, 4 and 6 months post-challenge. A major difference in the number of
infected animals between placebo group and the groups of vaccinated dogs during the post-
challenge period was noted (Fig 1). In the control group (n = 5), three and five dogs were cul-
ture positive at 4 months and 6 months respectively, whereas all the animals were PCR-positive
at every time point. By contrast, only two (culture-positive) and one (PCR-positive) out of five
dogs vaccinated with Cter-rPSA were found parasite-positive at 4 months and only one
remained infected (PCR- and culture- positive) at 6 months. Similarly, one (11.1%) and two
(22.2%) out of 9 dogs vaccinated with rPSA were found culture- and PCR- positive at 4 months
and 6 months, respectively. Parasite loads are shown in Fig 1C. Mean values were significantly
Fig 1. Parasitological evaluation of placebo and vaccinated dogs. The presence of (A) live Leishmania
parasites was highlighted by subculture analysis of bone marrow aspirates isolated from dogs of placebo
(n = 5), rPSA/QA-21 (n = 9) and Cter-rPSA (n = 5) groups at 2, 4 and 6 months post-challenge (PC). A sample
was considered as positive when Leishmania parasites were detected during the seeding or subculture
analysis. The presence of (B) Leishmania DNA and (C) the parasite load in bone marrow aspirates of dogs of
each group were assessed by quantitative PCR. Dogs were considered as positive when the titer was
superior to 40 parasites per mL. Data are expressed as (B) the number of dogs with positive PCR at each
time points post-challenge and (C) the mean number of parasites per mL of bone marrow aspirates at
different times post-challenge (4 and 6 months) (* p<0.05, ** p<0.01, *** p<0.001).
doi:10.1371/journal.pntd.0004614.g001
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lower in vaccinated dogs (rPSA: p = 0.019 and 0.004; Cter-rPSA: p = 0.018 and 0.031) than in
placebo group at 4 and 6 months post-infection, respectively.
Humoral immune response
As shown in Fig 2, specific IgG2 antibody responses against rPSA (A), Cter-PSA (B) and LiE-
SAp (C) were assessed by ELISA in all serum samples. A weak specific IgG2 response was mea-
sured in all dogs immediately before immunization and in dogs from the placebo group at
different times post-immunization: 1 month after the second dose of vaccine and 2 months
after the third dose. Dogs vaccinated with rPSA/QA-21 and Cter-rPSA/QA-21 had signifi-
cantly higher levels of anti-LiESAp [except for Cter-rPSA group: p = 0.0420 and p = 0.4206,
respectively (Fig 2C)], anti-rPSA [p = 0.0033 and p = 0.0010, respectively (Fig 2A)] and anti-
Cter-rPSA [p = 0.0119 and p = 0.0079, respectively (Fig 2B)] antibodies. IgG2 antibodies were
detected as early as one month after the second vaccine candidate injection compared to pla-
cebo group for the same period. Specific IgG2 antibody titers remained significantly higher in
vaccinated dogs compared to those of placebo animals two months after the third injection.
Overall, IgG2 anti-leishmanial response was significantly higher in vaccinated groups com-
pared to placebo group.
Viability of L. infantum promastigotes untreated or treated for 30 min with placebo dog
sera collected two months after the third injection was nearly identical. More than 90% of pro-
mastigotes remained healthy and viable (data in S1 Fig). In contrast, a 30 min exposure of pro-
mastigotes with vaccinated dog sera at the same time point revealed around 45% of viability.
The anti-proliferative effects on L. infantum promastigote growth were evaluated by exposing
parasites 30 min to serum samples from placebo and vaccinated dogs [rPSA (n = 9) or Cter-
rPSA (n = 5)], washing and culturing for 72 h under standard culture conditions. As shown in
Fig 3, promastigote treatment with placebo dog sera did not affect parasite’s growth during the
whole culture time. However, an inhibitory effect was evidenced on the growth of promasti-
gotes previously incubated with vaccinated dog sera collected two months after the third injec-
tion (rPSA: p = 0.0010, Cter-rPSA: p = 0.0079, respectively).
Macrophage anti-leishmanial activity
Macrophage ability to kill L. infantum when pre-infected macrophages were cultured in pres-
ence of autologous lymphocytes, expressed as percentage of parasite inhibition index, is pre-
sented in Fig 4. Anti-leishmanial activities were evaluated immediately before immunization
and two months after the third injection. At starting point, the assay did not reveal any signifi-
cant anti-leishmanial activity in any of the dogs, either placebo or vaccinated groups (Fig 4). By
contrast, statistical differences were obtained between vaccinated and placebo groups two
months after the completion of vaccine administration. As shown in Fig 4, higher anti-leish-
manial activities were evidenced by infected macrophages from dogs vaccinated with rPSA/
QA-21 or Cter-rPSA/QA-21 after co-culture with autologous lymphocytes, as demonstrated by




-(NO derivatives) measurements in supernatants of co-cultured cells were
directly correlated with NO pathway activation and parasite intracellular killing (Fig 5A). NO
production in supernatants of all co-cultures was measured prior to immunization and two
months after the third injection. Placebo dogs-infected macrophages synthesized low NO levels
(around 0.6 nmol/105 cells/72 hours) at the different time points analyzed prior to immuniza-
tion and two months after the third injection. As shown in Fig 5A, the NO levels produced by
macrophages from vaccinated dogs (rPSA/QA-21 and Cter-rPSA/QA-21) were significantly
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Fig 2. Vaccine specific serological responses as detected by Enzyme-Like Immunosorbent Assay
(ELISA). Evolution of levels of (A) anti-rPSA, (B) anti-Cter-rPSA and (C) anti-LiESAp specific IgG2 antibodies
was assessed in serum samples isolated from dogs of each group immediately before immunization and at
different times post-immunization: first month after the second dose and two months after the third dose.
Each serum sample was tested in triplicates. Cut-off value was calculated using the following formula: mean
OD in sera from all dogs before immunization + 3 standard deviations. Values represent means OD +/-
standard deviation of triplicate experiments (* p< 0.05, ** p<0.01, *** p<0.001).
doi:10.1371/journal.pntd.0004614.g002
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higher (20.75 +/- 4.88 nmol/105 cells/72 hours, p = 0.0009 and 12.24 +/- 4.48 nmol/105 cells/72
hours, p = 0.0069, respectively) than those evaluated before vaccination (0.52 +/- 0.06 nmol/
105 cells/72 hours) and in cell supernatants from placebo dogs 2 months after the vaccine
course (0.50 +/- 0.07 nmol/105 cells/72 hours). Moreover, the mean value was significantly
Fig 3. Effect of immunized dog sera on the proliferation of L. infantum promastigotes. The anti-
proliferative effects were assessed on the growth of L. infantum promastigotes previously exposed for 30 min
to serum samples from placebo (n = 5) and vaccinated dogs [rPSA (n = 9) or Cter-rPSA (n = 5)], collected
before immunization and at 2 months post-vaccination, and then washed and cultured for 3 days at 25°C in 5
mL of RPMI medium supplemented with 20% foetal calf serum (FCS). At day 3, parasites were counted by
flow cytometry (FACSCanto, Becton Dickinson) to assess cellular viability and parasite concentration.
Results are expressed in percentage of promastigote growth inhibition +/- standard deviation (* p<0.05,
** p<0.01, *** p<0.001).
doi:10.1371/journal.pntd.0004614.g003
Fig 4. Anti-leishmanial activity of caninemonocyte-derived macrophages in non-immune and
immune dogs. The ability of pre-infected canine monocyte-derived macrophages to kill Leishmania parasites
when they were exposed to autologous peripheral lymphocytes derived from PBMC was expressed as the
percentage of parasitic index inhibition after in vitro infection with Leishmania infantum promastigotes
(MHOM/MA/67/ITMAP-263) and 72 h incubation with and without autologous lymphocytes. Anti-leishmanial
activity of co-cultured canine macrophages was evaluated immediately before immunization and two months
after the third dose. Values represent means +/- standard deviation of duplicate experiments (* p< 0.05,
** p<0.01, *** p<0.001).
doi:10.1371/journal.pntd.0004614.g004
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increased in the group of dogs vaccinated with rPSA/QA-21 compared to the group of dogs
vaccinated with Cter-rPSA/QA-21 (p = 0.012).
Cytokine measurements
Cytokine contents in culture supernatants from placebo and vaccinated dogs were assessed
prior to immunization and at two months after the third injection. As indicated in Fig 5B,
prior to immunization, cell culture supernatants from all dogs expressed low IFN-γ levels
(around 0.05 ng per mL). No increase in IFN-γ level was measured in supernatants of
Fig 5. NO derivative and IFN-γ productions by 72 hours co-cultured caninemacrophages from
placebo and vaccinated groups of dogs (rPSA and Cter-rPSA). (A) NO3
-/NO2
- accumulation in the same
samples was used as an indicator of NO production by activated macrophages and was assayed using the
modified Griess reaction according to Pinelli et al. [64]. (B) IFN-γ levels were determined by a two-site
sandwich ELISA in cell culture supernatants of 72 h co-cultured cells. Values represent means +/- standard
deviation of triplicate experiments (* p< 0.05, ** p<0.01, *** p<0.001).
doi:10.1371/journal.pntd.0004614.g005
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co-cultured pre-infected macrophages from placebo group two months after the third injec-
tion. By contrast, in supernatants of pre-infected macrophages co-cultured with autologous
lymphocytes from rPSA/QA-21- or Cter-rPSA/QA-21-vaccinated dogs, significant higher
IFN-γ levels were measured (1.98 +/- 0.66 ng/mL, p = 0.0010 and 1.99 +/- 0.59 ng/mL,
p = 0.0079, respectively) than in those from placebo (0.060 +/- 0.007) or pre-immune dogs
(0.052 +/- 0.006) (Fig 5B).
IL-4 and IL-10 levels in co-culture supernatants from all groups were low and not signifi-
cantly different prior to immunization, and 2 months after completion of the vaccination pro-
tocol (data in S2 Fig).
Discussion
In this study, we report that naive dogs immunized thrice with either the recombinant ES
LaPSA-38S (rPSA) or its recombinant C terminal part LaPSA-12S, (Cter-rPSA), and combined
with QA-21 as adjuvant, conferred a marked protection against L. infantum promastigote
infection. A negative bone marrow parasite load was evidenced in 77.8% and 80.0% vaccinated
dogs respectively at 6 months post-challenge follow-ups. The parasite burden was significantly
reduced in three infected vaccinated dogs, but the short term survey did not allow the observa-
tion of any delayed disease progression or a role as reservoirs.
Investigations on potential Leishmania antigen screening and best adjuvant for vaccines
have required substantial effort [11,43]. First vaccine attempts based on killed or attenuated
parasites, conceptually simple to produce in endemic areas at low cost, gave disappointing
results in field trials [9,44]. Second-generation vaccines are now available. Only two dog vac-
cines achieved successful results in Phase III trials: 1- Leishmune (Fort Dodge Animal Health),
based on a glycoproteic complex (fucose mannose ligand) from L. donovani adjuvanted with
QS-21 and deacylated saponins of Quillaja saponaria, licensed and used in Brazil [11,45,46]
and 2- CaniLeish (Virbac Animal Health) a formulation related to the LiESAp vaccine using L.
infantum promastigote ES antigens from culture supernatant combined to QA-21 as adjuvant
[22,25,27,28,47,48], licensed and marketed in Europe since 2011. A primary vaccination course
of three injections at three week intervals, followed by annual booster vaccinations, is required
with CaniLeish. The same protocol including two booster injections was scheduled in this
study, which represent an important drawback in endemic areas. Various Leishmaniamole-
cules have already been reported as promising vaccine candidates (reviewed by [49,50]), how-
ever very few recombinant vaccines have succeeded beyond the laboratory rodent stage. This
in part is linked to laboratory animal models which do not mimic natural infection. Only
LeishTec vaccine (recombinant A2 antigen plus adjuvant) led partial protection (40%) versus
L. chagasi promastigote challenge and has been marketed as a canine vaccine (Hertape Calier)
in Brazil. Other vaccine candidates, such as the multicomponent Leish-111f fusion protein
including TSA, LmSTI1, and LeIF antigens [31,51], gave disappointing results in dogs. Simi-
larly, trials with recombinant cysteine peptidases plus canine IL-12, or recombinant Histone
H1, hydrophilic acylated protein B1, or Leishmania activated C kinase receptor (LACK) ana-
log, did not protect dogs from Leishmania infection [52]. We report here a successful vaccina-
tion study with recombinant Leishmania proteins in dogs. Efficacy of vaccination was
corroborated by both qPCR and culture methods and clear differences in humoral and cellular
immunity were evidenced between placebo and vaccinated groups.
Our results demonstrated clear-cut immune response differences between vaccinated and
placebo dogs. An early increase in specific IgG2 antibodies, correlated with protection, was
only evidenced in rPSA/QA-21- and Cter-rPSA/QA-21-immunized dogs. The IgG1 antibodies
are associated with susceptibility, disease severity and correlates with a Th2 response [53–55],
Excreted/Secreted PSA Protection in Dogs
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while IgG2 are predominant in naturally resistant or vaccinated dogs and are associated with
an appropriate Th1-dominant response [56–58]. More recently, we provided direct evidence
that cooperation of both humoral and cellular immune response might be essential for protec-
tion in LiESAp/muramyl dipeptides immunized dogs [22]. We demonstrated here that inacti-
vated sera from rPSA/QA-21- or Cter-rPSA/QA-21-vaccinated dogs supported promastigote
killing and a significant parasite growth culture inhibition. Our data evidenced that an appro-
priate antibody response, such as mediated by anti-rPSA and anti-Cter-rPSA antibodies, might
play a major role in canine VL protection.
Recent technological advances have allowed a global analysis of Leishmania secretome
[59,60]. However, secretome functions are poorly known since few of these molecules have
been extensively characterized [59,61]. Analysis of recombinant rPSA and Cter-rPSA amino
acid sequences reveal that Cter part contains a Threonine/Serine-rich domain and Proline/Cys-
teine-rich regions. These regions are relatively conserved between Leishmania species but their
lengths vary considerably and they can be totally absent in some PSAs [33]. The immunodomi-
nant humoral and cellular responses to this region might be linked to its proteolytic stability
and hydrophobicity [36,42,62]. This suggests that ES PSA might have an important immuno-
regulatory role between parasites and their target cells and on the immune responses. Promas-
tigotes might secrete PSA to modify macrophage functions even before parasite engulfment.
Analogously, amastigotes secrete PSA, which might be transported across the parasitophorous
vacuole membrane, to interfere with macrophage signaling pathways, thereby preventing mac-
rophage activation. So, future candidates might exist in Leishmania ES proteins and be used for
new generation vaccine design.
Intracellular Leishmania parasite killing by macrophages is essential for cure. We previously
developed an ex vivo canine macrophage-autologous lymphocyte co-culture system to investi-
gate protective cellular response. This co-culture system was used to analyze NO pathway
involved in macrophage parasite killing. Increased IFN-γ and NO production, as well as anti-
leishmanial macrophage activity, were verified only in vaccinated dogs, and lasted two months
after the full vaccination course. This further argues that Leishmania killing is mediated via an
L-arginine NO pathway, induced by Th1 cytokines, mainly IFN-γ. All these points support the
hypothesis that ES PSA and its carboxy terminal part, in recombinant forms, induce protection
in canine VL by inducing a Th1-dominant immune response and an appropriate specific anti-
body response. In addition, the nature and magnitude of immune responses revealed by PSA
formulations is very similar to those induced by the different LiESAp formulations. This sug-
gests that ES PSA is one of the main active compounds of the already licensed CaniLeish. As
NO and IFN-γ are also involved in human leishmaniasis [63], monitoring these parameters
might represent markers of a protective response for recombinant PSA or its carboxy-terminal
part-based vaccine development and for large scale field studies. Altogether, these results,
obtained in this experiment with a limited number of animals and with a short term survey,
deserve further investigations to evaluate these vaccine candidates against a severe disease for
both humans and dogs in natural conditions of infection.
Materials and Methods
Production and purification of vaccine candidates: LaPSA-38S (rPSA)
and LaPSA-12S (Cter-rPSA) recombinant proteins
Preparation of LaPSA-38S (rPSA) recombinant protein. The LaPSA-38S gene (Gen-
Bank accession number: FJ974054, http://www.ncbi.nlm.nih.gov/genbank), was cloned and
identified as previously described [32], and was amplified from pBluescript-SK vector by PCR
with Phusion High-Fidelity DNA Polymerase (Finnzymes) using the following primers:
Excreted/Secreted PSA Protection in Dogs
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forward primer, F-PSA-38S (5’-CCATGGCGCAGTGCGTGCGTCGG-3’) and reverse primer,
R-PSA-38S (5’-GCGGCCGCGTGATGGTGATGGTGATGATCGTGGTTCGCCAG-3’), con-
taining Ncol and Notl restriction sites in each 5' end (underlined). DNA amplification was per-
formed according to the following protocol: 5 min hot-start at 95°C followed by 30 cycles of
95°C for 30s, 62°C for 30s and 72°C for 90s, and a final extension at 72°C for 10 min. The puri-
fied PCR product was cloned in pCR2.1-TOPO TA vector using TOPO TA cloning Kit (Invi-
trogen) according to the manufacturer’s procedures. The transformed TOP10 E. coli cells
(Invitrogen) were screened for the presence of recombinant plasmid with the LaPSA-38S insert
by gene-specific PCR and analyzed with Ncol and Notl restriction enzymes. Isolated positive
clones were sequenced. The insert was removed by Ncol and Notl digestion and subcloned into
the Ncol and Notl insertion site of Leishmania expression vector pF4X1.4sat1 allowing selection
with the antibiotic Nourseothricin to create the recombinant pF4X1.4-LaPSA-38S plasmid.
The resulting construct, encoding a full sequence of LaPSA-38S secreted protein, was fused to
a C-terminus (His6)-tag. L. tarentolae promastigotes were successfully maintained in continu-
ous culture by successive passages of 5 x 105 flagellates/mL every week into 10 mL of
completely defined CDM/LP medium free of serum, macromolecules, proteins and cell con-
taminants as previously described [29]. For stable integration of the expression cassette into
the 18S ribosomal RNA (ssu) locus, 10 μg of pF4X1.4sat1 plasmid containing LaPSA-38S gene
was digested by SwaI restriction enzyme. Transfections of L. tarentolae promastigotes were
performed by electroporation in 2 mm cuvettes using a Gene Pulser II (Biorad), a single pulse
(5–6 msec) with the settings 450 V and 450 mF. After transfection, cells were transferred into a
fresh CDM/LP medium [29]. 100 μg/mL of Nourseothricin was added 24 h after electropora-
tion to select stable transformants. One week later, only nourseothricin-resistant cells survived.
Transgenic cells were selected as single colonies on the supplemented CDM/LP-agar medium
containing 100 μg/mL Nourseothricin (Jena Bioscience, Germany) as selective antibiotic. Mass
culture and protein purification were manufactured by Virbac Company in GMP conditions.
Culture amplifications were performed on CDM/LP medium. The culture supernatant con-
taining L. amazonensis ES LaPSA-38S, released by the parasite during its growth, was recov-
ered at the late stationary phase of growth. The only proteins in the medium, with their native
conformation, are parasite-produced. Recombinant ES PSA was purified from concentrated
culture supernatant through Ni-NTA affinity chromatography. This purified recombinant
LaPSA-38S protein migrated as a 45 kDa band in SDS–PAGE gel [24].
Preparation of recombinant LaPSA-12S (Cter-rPSA) protein. The LaPSA-12S gene
(GenBank accession number: FJ974053) is a truncated LaPSA-38S gene corresponding to the
C-terminal part of LaPSA-38S named Cter-rPSA, as previously described [32]. LaPSA-12S is a
polypeptide of 119 amino acids with a calculated molecular weight of 11.9 kDa. A pBluescript-
SK vector with the cDNA encoding for LaPSA-12S gene was digested with specific endonucle-
ases BamHI and KpnI (Eurogentec), compatible with multiple cloning site of pQE-31 vector
(Qiagen). The final BamHI–KpnI-generated DNA fragment was extracted from agarose gel
and purified using Wizard DNA clean-up system (Promega) following the manufacturer’s pro-
cedures. The purified DNA fragment was used in a ligation reaction in the presence of the
BamHI–KpnI-digested and dephosphorylated pQE31 vector. The ligation product was trans-
formed and propagated in E. coliM15 strain (Stratagene), purified and sequenced in both
strands. The clones containing the correct coding frame were selected and used to prepare and
purify the recombinant protein. Cter-rPSA was purified with Ni-NTA affinity chromatogra-
phy. This purified truncated recombinant LaPSA-12S protein migrated as a 16 kDa and 36
kDa bands in non-reduced SDS–PAGE gel. The band of 36 kDa corresponds to the 16 kDa
dimer form (S3 Fig).
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Animals and study design
Nineteen young adult dogs, 10 males and 9 females, between 2 and 4 years old, were selected
on clinical and serological criteria from a colony of naive Beagles from the kennel CEDS
(Domaine des Souches, Mezilles, France). Dogs were housed at the animal facility of the
National Veterinary School of Lyon (ENVL, France) in the “Unité d’Etudes PréCliniques”
(UEPC) during the time course of the experiment under conditions designed to exclude any
possible natural leishmanial infections. They were well-fed animals under constant scrutiny of
health problems by a veterinarian and had all received their yearly routine vaccinations. Care
and management of dogs were carried out according to ethical guidelines laid down in the
National Veterinary School of Lyon (ENVL). Protocols were submitted to and approved by
ethics committee of the ENVL (N° ICLB 135/08) and performed according to recommenda-
tions to limit the number of animals and long-term experimentations. All dogs had a specific
code/ID throughout the experiment. The animals were maintained in quarantine for a period
of 30 days before the initiation of the experiment. Prior to vaccination, blood was collected and
then sera and genomic DNA of all dogs were separated and extracted in order to exclude any
infected dog. Beagles were randomized by sex and age into three experimental groups and the
study was performed in a double–blind randomized fashion. Dogs of each group received three
subcutaneous injections at a 4-week interval of either freeze-dried dose of 1 mL buffer saline
(Placebo group, n = 5), 25 μg recombinant LaPSA-38S adjuvanted with 60 μg QA-21 (rPSA
group, n = 9) or 25 μg recombinant LaPSA-12S formulated with 60 μg QA-21 (Cter-rPSA
group, n = 5). Two months post-immunization, all dogs were challenged by intravenous injec-
tion of 108 infective promastigotes of L. infantum (MHOM/MA/67/ITMAP-263 strain, clone
2). Primary cultures of virulent promastigotes, differentiated from amastigotes isolated from
the spleen of heavily infected mice (BALB/c), were used for the virulent challenge.
Detection of specific IgG2 to rPSA, Cter-rPSA and LiESAp by Enzyme-
Linked Immunosorbent Assay (ELISA)
Specific IgG2 antibody responses against rPSA, Cter-rPSA and LiESAp were measured in the
serum samples of control and vaccinated dogs by a standard ELISA procedure. Briefly, sera
from immune or control dogs were added in triplicate at 1/50 dilution in PBS containing
0.05% Tween-20 to 96-well plates previously coated with rPSA (0.1 μg per well, batch
#A50054), Cter-rPSA (0.1 μg per well, batch #070425) or LiESAp (1 μg per well, batch #0011).
After 1 h incubation at 37°C, plates were washed extensively with PBS-0.05% Tween-20 and
incubated for 30 min at 37°C with secondary antibody (horseradish peroxidase-conjugated
sheep anti-dog IgG2, 1/5000). After three washes in PBS-0.05% Tween-20, plates were devel-
oped with OPD substrate (with H2O2 in citrate buffer) and absorbance was read using micro-
plate reader at 492 nm wavelength. For analysis, a threshold of positivity was estimated by
calculating a cut-off using the following formula: mean OD in sera collected from all dogs at
the starting point (before immunization) + 3 standard deviations.
Effect of sera from unvaccinated and vaccinated dogs on the
proliferation of Leishmania infantum promastigotes
Promastigotes of Leishmania infantum were collected by centrifugation and washed three
times in PBS. A total of 5x106 parasites were incubated (or not) with 100 μL of complement
heat-inactivated serum of dog for 30 min, at dilution ¼ in culture medium. These sera were
collected from all dogs 2 months after vaccination. Cell’s viability was assessed by trypan blue
staining, the parasites were washed three times in PBS, and then cultivated at 25°C in 5 mL of
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RPMI medium supplemented with 20% heat-inactivated foetal calf serum (FCS). Parasites
were counted daily for three days by flow cytometry (FACSCanto, Becton Dickinson). Results
are expressed in percentage of promastigote growth inhibition at day 3.
Assessment of canine monocyte-derived macrophages anti-leishmanial
activity
Peripheral Blood Mononuclear Cells (PBMC) were obtained from heparinized peripheral
blood by density centrifugation through Ficoll-Hypaque (GE Healthcare Life Sciences). Canine
monocyte-derived macrophages (CM-DM) and non-adherent cells (i.e. lymphocytes) were
prepared by differential adherence of PBMC as previously described [25,27]. CM-DM sepa-
rated from lymphocytes were cultured for 5 days at 37°C and 5% CO2 in RPMI 1640 medium
(BioWhittaker), supplemented with 2 mM glutamine, 10% heat-inactivated FCS, 100 μg/mL
streptomycin and 100 IU/mL penicillin. They were infected with stationary-phase promasti-
gotes of L. infantum (MHOM/MA/67/ITMAP-263 strain, clone 2) at a parasite: macrophage
ratio of 5:1 for 150 min in LabTek 16-well glass chamber slides. Non-internalised parasites
were removed by gentle washing. The cells were checked to verify that greater than 40% were
infected. Infected macrophages were then incubated alone or in the presence of autologous
lymphocytes at a lymphocyte: macrophage ratio of 2:1. After a 72 h co-culture, supernatants
were collected for further analyses and the lymphocytes were removed by gentle washings.
Macrophages were fixed with methanol and stained with Giemsa in order to determine the par-
asitic index. For assessment of anti-leishmanial activity, the percentages of infected cells and
the number of amastigotes per macrophage were estimated in duplicate experiments by micro-
scopic examination of Giemsa-stained preparation and were used to calculate the parasite
index (PI) inhibition. Percentage of PI inhibition = 100 –[(mean number of amastigotes per
macrophage × percentage of infected macrophages when macrophages were incubated with
autologous lymphocytes) / (mean number of amastigotes per macrophage × percentage of
infected macrophages in untreated macrophages)] × 100.
Cytokine and nitric oxide measurements
NO3
-/NO2
- accumulation in supernatants from 72 h co-cultured cells (pre-infected macro-
phages exposed to autologous lymphocytes) was used as an indicator of NO production by
activated macrophages and was assayed by the Griess reaction using the nitrate/nitrite colori-
metric assay of Alexis biochemicals (Enzo Life Sciences, France). The Griess reagent was modi-
fied according to Pinelli et al. [64].
IFN-γ, IL-4 and IL-10 levels were determined as previously described [25] in cell culture
supernatants by a two-site sandwich ELISA using specific anti-dog IFN-γ (2 μg/mL), anti-dog
IL-4 (1 μg/mL) and anti-dog IL-10 (1 μg/mL) antibodies (R&D Systems, Minneapolis, USA),
biotinylated anti-dog IFN-γ (100 ng/mL), anti-dog IL-4 (50 ng/mL) and anti-dog IL-10 (50 ng/
mL) antibodies (R&D Systems, Minneapolis, USA) and streptavidin conjugated to horseradish
peroxidase (1/200) (R&D Systems, Minneapolis, USA). Absorbance values were read at 490
nm wavelength in an automatic microplate reader (Wallac Victor21420 Multilabel counter,
Perkin-Elmer life sciences). Standard curves for IFN-γ, IL-4 and IL-10, respectively, were per-
formed by the use of recombinant canine proteins (R&D Systems, Minneapolis, USA).
Clinical follow-up and assessment of parasite load
The health status of the animals was routinely followed by veterinarians (including appetite,
physical examination and physical activity). The dogs were monitored for 3 weeks after each
injection. Local tolerance was investigated by direct visual examination and any lesions were
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scored daily over a period of 14 days after each injection. General tolerance was investigated by
means of a weekly general clinical examination and a daily general health evaluation with rectal
temperature measurement. Body weights were measured once a week throughout the trial
period.
Dogs were monitored for parasite establishment and subsequent development of the disease
by routine screening for classical clinical signs and parasite isolation. Infection was assessed at
2, 4 and 6 months post-challenge. For that, dogs were anesthetized and bone marrow aspirates
were collected by sternal puncture into citrate tubes to assess parasite load.
The presence of Leishmania parasites was determined by culturing parasites in NNN
biphasic medium at 25°C. Bone marrow samples (about 500 μl) were cultured in NNN biphasic
medium (containing 2 mL of RPMI-20% heat-inactivated FCS) for 1 week. Subcultures were
weekly realized by adding 0.5 mL or 1 mL of culture sample in NNNmedium containing 3 mL
of RPMI-20% FCS (4 subcultures). The presence of parasites was determined by regular micro-
scopic observation for 20 min in an inverted microscope at 400x magnification. When parasites
were observed, the sample was considered as parasite positive.
The presence of LeishmaniaDNA was also assayed in bone marrow samples of all the
enrolled dogs by real-time quantitative PCR (qPCR) as previously described for kinetoplast
DNA amplification [65]. After lysis, the DNA of each bone marrow sample was extracted using
a silica column (QIAamp DNAmini kit). The Stratagene (La Jolla, California, USA) MX 4000
system was used for amplification and detection. Optimization experiments led us to use the
Stratagene qPCRmaster mix, 15 pmol of forward primer (CTTTTCTGGTCCTCCGGGTAGG),
15 pmol of reverse primer (CCACCCGGCCCTATTTTACACCAA), and 50 pmol of TaqMan
probe (FAM-TTTTCGCAGAACGCCCCTACCCGC-TAMRA). Assays were performed with a
25 μL final volume with 1 μL of DNA sample. The standard curve was established from Leish-
maniaDNA extracted from 5 × 106 parasites; 1 μL of each serial dilution, ranging from 50,000
to 0.0001 parasites, was introduced into reaction tubes. TaqMan chemistry allowed two-step
temperature (94 and 55°C) cycling over 45 cycles. Comparative quantification was performed by
using a single copy gene, the DNA polymerase gene, as a normalizer. Primers and a probe
described previously by Bretagne et al. [66] (TGTCGCTTGCAGACCAGATG [200 pmol],
GCATCGCAGGTGTGAGCAC [200 pmol], and VIC-CCAGGCTCGAAGTTGTTGCTGC
CC-TAMRA [200 pmol]) and the same working conditions as previously described for kineto-
plast DNA amplification were used. Results were expressed as the number of parasites per mL of
bone marrow aspirate. A sample was considered as positive when the established parasite con-
centration was superior to 40 parasites per mL.
Statistical analysis
Data analysis was performed with GraphPad Prism version 5.03 for Windows, GraphPad Soft-
ware (San Diego, California USA). Statistical significance of differences between groups was
determined by Mann-Whitney-Wilcoxon test. A p-value 0.05 was considered significant.
Ethics statement
The ENVL Ethical Committee approval confirms that this study was carried out in accordance
with the G.R.I.C.E. “Ethical Committee Regulation applied to animal experimentation” guide-
lines (implemented in France in 2008) under project number 135.08.
Supporting Information
S1 Fig. Effect of immunized dog sera on the proliferation of L. infantum promastigotes.
Promastigotes of L. infantum are exposed for 30 min to serum samples from placebo (n = 5)
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and vaccinated dogs [rPSA (n = 9) or Cter-rPSA (n = 5)], collected before immunization and 2
months post-vaccination. Cellular viability was assessed by flow cytometry (FACSCanto, Bec-
ton Dickinson) just after exposure. Values represent average percentage of promastigote viabil-
ity +/- standard deviation ( p<0.05,  p<0.01, p<0.001).
(TIF)
S2 Fig. IL-4 and IL-10 productions by co-cultured cells from placebo and vaccinated (rPSA
and Cter-rPSA) groups of dogs. (A) IL-4 and (B) IL-10 levels were determined by a two-site
sandwich ELISA in cell culture supernatants of 72 h co-cultured cells. Values represent means
+/- standard deviation of triplicate experiments.
(TIF)
S3 Fig. Analysis of the production and purification of recombinant LaPSA-12S protein by
using Coomassie-stained SDS-PAGE gel. (lane 1) 5 μg of the purified recombinant LaPSA-
12S, (lane 2) 10 μg of the purified recombinant LaPSA-12S, (lane 3) SeeBlue Pre-stained Stan-
dard. Staining by Coomassie blue reveals a band of about 16 kDa corresponding to the LaPSA-
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